Analysis of the frequency of oncogenic driver mutations and correlation with clinicopathological characteristics in patients with lung adenocarcinoma from Northeastern Switzerland

被引:20
|
作者
Grosse, Alexandra [1 ]
Grosse, Claudia [2 ]
Rechsteiner, Markus [3 ]
Soltermann, Alex [1 ]
机构
[1] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Clin Pathol, Ramistr 100, CH-8091 Zurich, Switzerland
[2] Kepler Univ Hosp, Inst Pathol, Krankenhausstr 9, A-4021 Linz, Austria
[3] Univ Hosp Zurich, Inst Pathol & Mol Pathol, Diagnost Mol Pathol, Ramistr 100, CH-8091 Zurich, Switzerland
关键词
Lung adenocarcinoma; EGFR; KRAS; ALK; RET; ROS1; BRAF; ERBB2; MET; PIK3CA; Non-small cell lung cancer; EML4-ALK FUSION GENE; KRAS MUTATIONS; CLINICAL CHARACTERISTICS; CANCER PATIENTS; EGFR; PIK3CA; MET; SPECTRUM; DOMAIN; TUMOR;
D O I
10.1186/s13000-019-0789-1
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
BackgroundMolecular testing of lung adenocarcinoma for oncogenic driver mutations has become standard in pathology practice. The aim of the study was to analyze the EGFR, KRAS, ALK, RET, ROS1, BRAF, ERBB2, MET and PIK3CA mutational status in a representative cohort of Swiss patients with lung adenocarcinoma and to correlate the mutational status with clinicopathological patient characteristics.MethodsAll patients who underwent molecular testing of newly diagnosed lung adenocarcinoma during a 4-year period (2014-2018) were included. Molecular analyses were performed with Sanger sequencing (n=158) and next generation sequencing (n=311). ALK, ROS1 and RET fusion gene analyses were also performed with fluorescence in situ hybridization and immunohistochemistry/immunocytochemistry. Demographic and clinical data were obtained from the medical records.ResultsOf 469 patients with informative EGFR mutation analyses, 90 (19.2%) had EGFR mutations. KRAS mutations were present in 33.9% of the patients, while 6.0% of patients showed ALK rearrangement. BRAF, ERBB2, MET and PIK3CA mutations and ROS1 and RET rearrangements were found in 2.6%, 1.9%, 1.9%, 1.5%, 1.7% and 0.8% of the patients, respectively. EGFR mutation was significantly associated with female gender and never smoking status. ALK translocations were more frequent in never smokers, while KRAS mutations were more commonly found in ever smokers. The association between KRAS mutational status and female gender was statistically significant only on multivariate analysis after adjusting for smoking.ConclusionThe EGFR mutation rate in the current study is among the higher previously reported mutation rates, while the frequencies of KRAS, BRAF, ERBB2 and PIK3CA mutations and ALK, ROS1 and RET rearrangements are similar to the results of previous reports. EGFR and KRAS mutations were significantly associated with gender and smoking. ALK rearrangements showed a significant association with smoking status alone.
引用
收藏
页数:14
相关论文
共 50 条
  • [21] Traditional Chinese Medicine Syndromes are Associated with Driver Gene Mutations and Clinical Characteristics in Patients with Lung Adenocarcinoma
    Yang, Jili
    Lu, Haiyan
    Jing, Niancai
    Wang, Bo
    Guo, Huanyu
    Sun, Shoukun
    Zhang, Yue
    EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2022, 2022
  • [22] Driver mutations of young lung adenocarcinoma patients with malignant pleural effusion
    Wu, Shang-Gin
    Liu, Yi-Nan
    Yu, Chong-Jen
    Yang, James Chih-Hsin
    Shih, Jin-Yuan
    GENES CHROMOSOMES & CANCER, 2018, 57 (10): : 513 - 521
  • [23] The Driver Mutations Of Lung Adenocarcinoma In Patients Aged 50 Years Or Younger
    Wu, S. -G.
    Yu, C. -J.
    Yang, C. -H.
    Shih, J. -Y.
    Yang, P. -C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [24] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Luka Brcic
    Marko Jakopovic
    Marija Misic
    Fran Seiwerth
    Izidor Kern
    Silvana Smojver-Jezek
    Franz Quehenberger
    Miroslav Samarzija
    Sven Seiwerth
    Diagnostic Pathology, 11
  • [25] Analysis of the frequency of EGFR, KRAS and ALK mutations in patients with lung adenocarcinoma in Croatia
    Brcic, Luka
    Jakopovic, Marko
    Misic, Marija
    Seiwerth, Fran
    Kern, Izidor
    Smojver-Jezek, Silvana
    Quehenberger, Franz
    Samarzija, Miroslav
    Seiwerth, Sven
    DIAGNOSTIC PATHOLOGY, 2016, 11 : 1
  • [26] Clinicopathological Characteristics and Mutations Driving Development of Early Lung Adenocarcinoma: Tumor Initiation and Progression
    Inamura, Kentaro
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2018, 19 (04)
  • [27] Comprehensive Analysis for Clinically Relevant Oncogenic Driver Mutations in 1131 Consecutive Lung Adenocarcinomas
    Arcila, M. E.
    Lau, C.
    Jhanwar, S.
    Zakowski, M. F.
    Kris, M. G.
    Ladanyi, M.
    LABORATORY INVESTIGATION, 2011, 91 : 404A - 404A
  • [28] Comprehensive Analysis for Clinically Relevant Oncogenic Driver Mutations in 1131 Consecutive Lung Adenocarcinomas
    Arcila, M. E.
    Lau, C.
    Jhanwar, S.
    Zakowski, M. F.
    Kris, M. G.
    Ladanyi, M.
    MODERN PATHOLOGY, 2011, 24 : 404A - 404A
  • [29] Relationship between driver gene mutations and clinical pathological characteristics in older lung adenocarcinoma
    Liu, Xia
    Jiang, Guopeng
    Sun, Xuefei
    Su, Guangfeng
    Zhang, Xuan
    Shen, Dan
    Yan, Na
    FRONTIERS IN ONCOLOGY, 2023, 13
  • [30] Somatic Driver Mutations In Normal Lung Parenchyma In Patients With Localized Pulmonary Adenocarcinoma
    Chalela, R.
    Bellosillo, B.
    Pijuan, L.
    Longaron, R.
    Badenes Bonet, D.
    Rodriguez-Fuster, A.
    Gea, J.
    Curull, V.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195